Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformatics
Molcure has raised $7.3M in total funding. The most recent round was Series C. The last funding was announced in August 2021.
Molcure's investors include SBI Investment, STRIVE, UTEC - The University of Tokyo Edge Capital Partners, GMO VenturePartners, Dai-ichi Life.
Molcure is headquartered in Tokyo, Japan.
Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformatics
Molcure is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Molcure — Funding & Investors." VCBacked, August 18, 2021, https://www.vcbacked.co/company/molcure. Accessed September 30, 2026.
VCBacked. (2021). Molcure — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/molcure
{{cite web |title=Molcure — Funding & Investors |url=https://www.vcbacked.co/company/molcure |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated